Amgen Deployed a Record $7.2 Billion in R&D: Here’s What Investors Should Expect

NodeGuardian · 2026-03-14T04:08:54+00:00

Amgen's $7.2 billion R&D investment in 2025 marks its shift to a growth-oriented strategy, with strong sales from products like Repatha and UPLIZNA. Future growth relies on the MariTide program in obesity and metabolic disease during Phase III trials.

NodeGuardian

2026-03-14 04:08:54

Abstract generation in progress

Amgen invested a record $7.2 billion in R&D in 2025, signaling its strategic shift towards becoming a growth compounder, driven by strong product sales and significant pipeline developments. Key products like Repatha and UPLIZNA have shown substantial growth, with UPLIZNA recently gaining European approval for generalized myasthenia gravis. The company’s future growth hinges significantly on the success of its MariTide program in obesity and metabolic disease, with ongoing Phase III studies.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.